Head-to-head comparison of two first-line regimens and an NRTI-sparing regimen for initial therapy of HIV-1 infection: what should we start?

Curr HIV/AIDS Rep. 2009 Feb;6(1):1-2. doi: 10.1007/s11904-009-0001-4.
No abstract available

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkynes
  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Benzoxazines / administration & dosage*
  • Benzoxazines / therapeutic use
  • Clinical Trials, Phase III as Topic
  • Cyclopropanes
  • Drug Administration Schedule
  • Drug Resistance, Viral
  • Drug Therapy, Combination
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1 / drug effects*
  • Humans
  • Lopinavir
  • Male
  • Pyrimidinones / administration & dosage*
  • Pyrimidinones / therapeutic use
  • Randomized Controlled Trials as Topic
  • Reverse Transcriptase Inhibitors / administration & dosage*
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Treatment Outcome

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • Pyrimidinones
  • Reverse Transcriptase Inhibitors
  • Lopinavir
  • efavirenz